New antibody drug shows promise for controlling severe eczema
NCT ID NCT06173284
Summary
This study tested a new injectable drug called 611 in Chinese adults with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug could safely reduce the severity of skin rashes and itching over a year of treatment. Researchers compared the drug's effects against a placebo in over 500 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Dermatology Hospital of Jiangxi Province
Nanchang, Jiangxi, 330200, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
The Fourth Affiliated Hospital Zhejiang University School of Medicine
Jinhua, Zhejiang, 322000, China
Conditions
Explore the condition pages connected to this study.